Target Name: MIR1200
NCBI ID: G100302113
Review Report on MIR1200 Target / Biomarker Content of Review Report on MIR1200 Target / Biomarker
MIR1200
Other Name(s): microRNA 1200 | MicroRNA 1200 | hsa-miR-1200 | hsa-mir-1200 | Hsa-mir-1200 | MIRN1200

MIR1200: A Potential Drug Target and Biomarker

MIR1200, also known as interleukin-12 (IL-12), is a cytokine that plays a crucial role in the regulation of immune and inflammatory responses. It is a cytokine that is expressed in various tissues and cells, including immune cells, epithelial cells, and epithelial-derived cells. MIR1200 has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune diseases, and infectious diseases.

MIR1200 is a member of the IL-12 family, which includes several cytokines that play a central role in the regulation of immune responses. IL-12 is a cytokine that is involved in the regulation of immune cell function and the development of cancer. It is produced by various types of immune cells, including T cells, B cells, and natural killer cells. MIR1200 is a potent cytokine that can induce various types of immune responses, including cell proliferation, differentiation, and inflammation.

MIR1200 has been shown to be involved in the regulation of cellular processes that are important for cancer progression. For example, studies have shown that MIR1200 can promote the growth and survival of various types of cancer cells, including breast, lung, and ovarian cancer cells. MIR1200 has also been shown to play a role in the regulation of the immune response, and it has been shown to enhance the activity of various immune cells, including natural killer cells and T cells.

MIR1200 has also been shown to be involved in the regulation of inflammatory responses. Studies have shown that MIR1200 can induce various types of inflammatory responses, including inflammation at the mucosal surface, inflammation in the liver and spleen, and inflammation in the bone marrow. MIR1200 has also been shown to play a role in the regulation of cellular processes that are important for the development of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

MIR1200 has also been shown to have potential therapeutic applications in the treatment of various diseases. For example, studies have shown that MIR1200 can be used to treat various types of cancer, including breast, lung, and ovarian cancer. MIR1200 has also been shown to be effective in the treatment of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

In addition to its potential therapeutic applications, MIR1200 has also been shown to have potential biomarker properties. Studies have shown that MIR1200 can be used as a marker for various types of cancer, including breast, lung, and ovarian cancer. MIR1200 has also been shown to be involved in the regulation of cellular processes that are important for cancer progression, and it has been shown to enhance the sensitivity of cancer cells to various types of treatments.

Overall, MIR1200 is a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of MIR1200 in cellular processes and its potential therapeutic applications. MIR1200 is a promising target for the development of new treatments for various types of cancer and autoimmune diseases.

Protein Name: MicroRNA 1200

The "MIR1200 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1200 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2 | MIR1256 | MIR1257 | MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126 | MIR1260A | MIR1260B | MIR1261 | MIR1262 | MIR1263 | MIR1264 | MIR1265 | MIR1266 | MIR1267 | MIR1268A | MIR1268B | MIR1269A | MIR1269B | MIR127 | MIR1270 | MIR1271 | MIR1272 | MIR1273A | MIR1273C | MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278 | MIR1279 | MIR128-1 | MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1 | MIR1285-2 | MIR1286 | MIR1287 | MIR1288 | MIR1289-1 | MIR1289-2 | MIR129-1 | MIR129-2 | MIR1290 | MIR1291 | MIR1292 | MIR1293